Published: Apr 27, 2021
CAMBRIDGE, Mass. (BUSINESS WIRE) Repertoire Immune Medicines, a clinical-stage biotech company decoding the immune synapse to create novel immune therapies for cancer, immune disorders, infectious disease, and other serious diseases, today announced the company has elected neuroscience researcher and educator, Susan Hockfield, Ph.D., President Emerita of MIT, to its board of directors.
John Cox, Chief Executive Officer, Board of Directors, Repertoire Immune Medicines
“Dr. Hockfield is a tremendous addition to Repertoire Immune Medicines, as a scientist, organizational leader, and public servant,” said John Cox, CEO of Repertoire. “Our company is positioned at the frontier of immune medicines based on our ability to understand the drivers of cellular immunity. The breadth and depth of Dr. Hockfield’s experiences will help guide us along the way.”